43
Participants
Start Date
February 18, 2021
Primary Completion Date
July 9, 2025
Study Completion Date
July 9, 2025
PXS-5505
PXS-5505 is a hard capsule (size 0) with the additional excipients mannitol and magnesium stearate.
National Taiwan University Hospital - Hematology And Oncology, Taipei
Chang Gung Medical Foundation - ChiaYi Chang Gung Memorial Hospital - Hematology and Oncology, Chiayi City
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City
Liverpool Hospital, Liverpool
St Vincent's Hospital Melbourne, Fitzroy
Ashford Cancer Centre Research, Adelaide
The Perth Blood Institute, West Perth
One Clinical Research, Perth
National Cancer Center (Seoul Metro; northern), Gyeonggi-do
Seoul National University Hospital - Bundang, Gyeonggi-do
Gachon University Gil Hospital, Incheon
Novant Health Cancer Institute, Winston-Salem
China Medical University Hospital - Internal Medicine - Taichung, Taichung
Keimyung University Dongsan Hospital, Daegu
Inje University Busan Paik Hospital - Internal Medicine, Busan
National Cheng Kung University Hospital, Tainan City
The University of Texas MD Anderson Cancer Center, Houston
Comprehensive Cancer Center (UAB CCC), Birmingham
Seoul National University Hospital, Seoul
Severance Hospital, Yonsei University Health System- Haemat, Seoul
Asan Medical Centre, Seoul
Samsung Medical Center, Seoul
The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul
Lead Sponsor
Syntara
INDUSTRY